| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013058 | HBV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS10013059 | HBV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS30000173 | HIV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS30010245 | HIV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS30006101 | HIV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS30006102 | HIV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS30032309 | HIV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS30032310 | HIV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS30032311 | HIV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
| TVIS20067511 | HPV | ENSG00000060982.15 | protein_coding | BCAT1 | No | No | 586 | P54687 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BCAT1 |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000517 |
| UniProt ID | P54687 |
| Regulation Type | |
| PubMed IDs | 17559390 |
| Citations | Smirnov SV, Samsonova NN, Novikova AE, Matrosov NG, Rushkevich NY, Kodera T, Ogawa J, Yamanaka H, Shimizu S: A novel strategy for enzymatic synthesis of 4-hydroxyisoleucine: identification of an enzyme possessing HMKP (4-hydroxy-3-methyl-2-keto-pentanoate) aldolase activity. FEMS Microbiol Lett. 2007 Aug;273(1):70-7. Epub 2007 Jun 6. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
